Ryan S. Sansom

Ryan S. Sansom

Ryan S. Sansom

Ryan Sansom, a partner in Goodwin’s Technology and Life Sciences Group, centers his practice on advising privately held and publicly traded emerging companies, with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, HCIT and health and wellness. Mr. Sansom’s representation of life science and technology companies spans the entire emerging company life-cycle, including pre-incorporation planning, formation and founder matters, seed, venture capital and growth equity financings, public offerings and mergers and acquisitions, and other complex transactions. In addition, Mr. Sansom often represents venture capital firms in connection with their investments in emerging companies and underwriters in connection with public offerings by emerging companies.


A selection of Mr. Sansom’s recent representations include:

Public Offerings

  • Ra Pharmaceuticals $105.4 million initial public offering
  • Dimension Therapeutics’ $72 million initial public offering
  • Imprivata’s $75 million initial public offering and $68.5 million follow-on public offering
  • Underwriters in the $65 million initial public offering, $85 million follow-on financing, $77 million follow-on financing and $74.5 million follow-on financing of a specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies
  • Vericel (f/k/a Aastrom Bioscience)’s $35 million follow-on public offering
  • BofA Merrill Lynch and Leerink Partners in the $60 million initial public offering of Roka Bioscience

Private Financings

  • Vensun Pharmaceuticals’ $22.5M Series C Financing from Deerfield Capital, Perceptive Advisors and JW Asset Management
  • Jounce Therapeutics’ $56 million Series B financing
  • Formlabs’ $1.8 million Series Seed financing, $19 million Series A financing and $35 million Series B financing
  • QPID Health’s $12.3 million Series B financing
  • BioDirection’s $4 million Series B financing
  • Elemental Machines’ Series Seed financing
  • 406 Ventures investment in Iora Health’s $28 million Series C financing
  • Bessemer Venture Partners’ venture investment in DocuTAP
  • Abingworth Life Sciences’ venture investment in Avedro
  • Lightstone Ventures’ venture investment in Catabasis

M&A Transactions

  • QPID Health in its sale to eviCore healthcare
  • Taris Biomedical in its sale of its Liris program to Allergan (NYSE: AGN)
  • Predictive Bioscience in its sale of its anatomic pathology business unit to Miraca Life Sciences
  • Onforce in its sale to the Adecco Group
  • Scientia Advisors in its sale to Precision Health

Mr. Sansom is a regular contributor to Founders Workbench, an online resource for start-ups, emerging companies and the entrepreneurial community.



J.D., 2007
Boston University School of Law
(cum laude)
B.A., 2004
Westfield State College
(summa cum laude)



Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers